Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.


BACKGROUND Non-vitamin K antagonist oral anticoagulant (NOAC) drugs are at least equivalent to warfarin for ischemic stroke prevention in patients with atrial fibrillation and have a lower risk of intracranial hemorrhage. The role of these agents in the prevention and treatment of other types of cerebrovascular disease remains unclear. METHODS We reviewed… (More)
DOI: 10.1212/WNL.0000000000001817